为您找到相关结果约500个

你是不是要搜索 期刊肺肉瘤样癌(PSC)新的治疗靶点——MET+Exon+14跳跃突变，沃利替尼能显身手 点击跳转

YYY MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance

Relationship of MET exon 14 splicing variants and MET exon 14 skipping expression in NSCLC FFPE samples

NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint

Characterization of MET exon 14 skipping in pancancer.

MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma

MET inhibitor resistance in patients with MET exon 14-altered lung cancers.

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

MET exon 14 skipping analogs: Rare but potentially clinically actionable.

Lung adenocarcinoma with MET exon 14 skipping mutation; clinicopathological characteristics and immunohistochemicalMET expression

MET Exon 14 Skipping: Doubling Up to Overcome Detection Challenges

Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations

为您找到相关结果约500个

共500条页码: 1/34页15条/页